Musc Foundation for Research Development

Medical University of South Carolina

Abbott Cardiovascular Systems, Inc.

Cardiac Pacemakers, Inc.

Novartis Ag

Bristol-Myers Squibb Compnay

Francis G Spinale

Rupak Mukherjee

Robert E Stroud

Michael R Zile

Eugene T Michal

Shubhayu Basu

Alexander James Sheehy

Tarek M Shazly

William M Torres

Craig Michael Stolen

Timothy Edward Meyer

Marc De Gasparo

Nicholas David Wold

Milan Seth

Michael Gold

Michael Looper

Anne Deschamps

Alexander Sheeny

Methods and systems for utilizing myocardial strain imaging in an inverse framework to identify mechanical properties of the heart and to determine structural and functional milestones for the development and progression to heart failure.

Non-invasive estimation of the mechanical properties of the heart

Embodiments of the disclosure are related to systems and methods for utilizing biomarker panel data with respect to medical devices and methods, amongst other things. In an embodiment, the disclosure can include a method of predicting the likelihood of response to CRT therapy. The method can include quantifying levels of one or more biomarkers in a biological sample of a patient, analyzing the quantified levels to determine response to CRT therapy, wherein a panel of biomarkers includes at least two selected from the group consisting of CRP, SGP-130, sIL-2R, sTNFR-II, IFNg, BNP, sST2, MMP-2, MMP-9, TIMP-1, TIMP-2, TIMP-4. Other embodiments are also included herein.

Systems and methods using biomarker panel data

A bioscaffolding can be formed within a post-myocardial infarct region sufficient to cause attenuation of a rate of myocardial infarct expansion. A bioscaffolding may further be formed in the post-myocardial infarct region to cause an increase in posterior left ventricular wall thickness. The gel or bioscaffolding can be formed from a mixture of gel components of different gelation systems. For example, a bioscaffolding can be formed by mixing at least two different components of at least two different two-component gelation systems to form a first mixture and by mixing at least two different components (other than the components that make up the first mixture) of the at least two different two-component gelation systems to form a second mixture.

Composition for modifying myocardial infarction expansion

Methods of modifying myocardial infarction expansion

Disclosed herein are methods of detecting and predicting diastolic heart failure and predicting congestive heart failure comprise protease and protease inhibitor profiling.

Detecting diastolic heart failure by protease and protease inhibitor plasma profiling

Provided are systems and methods for detecting and/or measuring in vivo interstitial biological activity, processes, and or compounds in human or animal subjects.

Systems and methods for in vivo measurement of interstitial biological activity, processes and/or compositions

Disclosed are methods and materials for assessing cardiac failure, cardiac hypertrophy, and left ventricular remodeling using microRNA levels. The level of microRNAs can be measured in a body fluid, such as plasma and serum.

Assessing left ventricular remodeling via temporal detection and measurement of microRNA in body fluids

Disclosed herein are methods of and systems for predicting recurrence of atrial fibrillation comprising protease and protease inhibitor profiling. The levels of matrix metalloproteinases (MMPs) and/or tissue inhibitor metalloproteinases (TIMPs) are analyzed to predict the recurrence of atrial fibrillation, and further to predict whether cardioversion will provide a successful therapy.

Predicting atrial fibrillation recurrence by protease and protease inhibitor profiling

Provided are devices and methods for treating a subject having a myocardial condition using sub-threshold electrical stimulation.

Devices and methods for treatment of myocardial conditions

Disclosed herein are methods of detecting or predicting diastolic heart failure in a subject, comprising identifying a profile of matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) from a body fluid of the subject that is associated herein with the existence of likely development of left ventricular dilation (LVD).

Predicting heart failure following myocardial infarction by protease and protease inhibitor profiling

Disclosed are methods of reducing fibrosis and adhesion formation in a surgical patient wherein the AT,receptor antagonist, the compound (S)-N-(1-carboxy-2-methylprop-1-yl)-N-pentanoyl-N-&lsqb;2&prime;(1H-tetrazol-5-yl)biphenyl-4-yl-methyl&rsqb;amine (valsartan) of formula

Method for reducing pericardial fibrosis and adhesion formation

The invention relates to the use of an N-substituted heterocyclic derivative and its pharmaceutically acceptable salts for the treatment or prevention of cardiac arrhythmia. These derivatives have the structure ##STR1##

Growing community of inventors

Charleston, SC, United States of America

Francis G Spinale